Nyheter

LIPIGON ENTERS LICENSING AND COLLABORATION AGREEMENT WITH COMBIGENE TO DEVELOP GENE THERAPY FOR LIPO

10 oktober, 2019

“We are very happy to enter this agreement with CombiGene ,” says Stefan K Nilsson, CEO at Lipigon. “Through the development of their epilepsy project, CombiGene has demonstrated a fantastic ability to handle the complexities of gene therapy. With our expertise in lipid biology this collaboration is a perfect match, ultimately aiming at improving the treatment for a patient group with few or no treatment options.” During the upcoming two years, the development of the lipodystrophy project will intensify. The main part of the work will be done at Lipigon and in close collaboration between the two companies.

Fler nyheter

10 november, 2022, Övrig nyhet

Triglycerider – de okända blodfetterna

25 augusti, 2020, Övrig nyhet

Lipigon-CombiGene collaboration reaches milestone

2 mars, 2016, Övrig nyhet

MIKAEL ELOFSSON INTERVIEWED AT ADD 2016

1 mars, 2016, Övrig nyhet

AVAILABLE POSITIONS

3 februari, 2016, Övrig nyhet

LIPIGON AWARDED CONNECT´S PITCH PRIZE

9 december, 2015, Övrig nyhet

LIPIGON PATENT APPLICATION PUBLISHED

1 september, 2015, Övrig nyhet

LIPIGON SCIENTISTS PUBLISH IN PRESTIGIOUS JOURNAL

27 juni, 2014, Övrig nyhet

LIPIGON SCIENTISTS IDENTIFIES LPL ACTIVATORS

26 januari, 2014, Övrig nyhet

LIPIGON ATTENDS: BIOTECH UMEÅ INVESTMENT DAY

17 januari, 2014, Övrig nyhet

LIPIGON ATTENDS: SWISS-SWEDEN

Nyheter

28 november, 2022, Pressmeddelande

Lipigons vd Stefan K. Nilsson ökar sitt innehav i bolaget

Lipigon Pharmaceuticals AB ("Lipigon") meddelar i dag att vd Stefan K. Nilsson har köpt aktier i Lip...

24 november, 2022, Pressmeddelande

Lipigon publicerar delårsrapport för januari-september 2022

Lipigon Pharmaceuticals AB ("Lipigon") publicerar i dag sin delårsrapport för perioden 1 januari-30 ...

14 november, 2022, Pressmeddelande

Umeå på börsen

Lipigon Pharmaceuticals AB ("Lipigon") anordnar tillsammans med andra börsnoterade bolag från Umeå e...